Clinical studies

Icon
ENTEROSORBENTS THERAPY IN CHILDREN WITH ASTHMA LIVING IN POOR SANITARY CONDITIONS, 2013

Zaytseva N. , Usitnova O.

SUMMARY: According to recent epidemiological and toxicological data, children living in poor sanitary conditions develop abnormal physical characteristics, such as morphological abnormalities and chronic diseases of the Central Nervous System and the respiratory, cardiovascular, musculoskeletal, endocrine and digestive Systems. Among the substances of industrial origin, an important role is played by metals that accumulate in the tissues and organs. The toxic effects are due to the type of metal, its concentration, the concurrence of other pathological factors and the general health conditions (immune reactivity, hypersensitivity, etc.). The study was conducted on 236 children suffering from mild asthma (experimental Group) living in areas close to metallurgical plants. The composition of the air – concerning the percentage of manganese, chrome, lead and nickel – was found to have values at the upper limits of standard. The control Group, homogeneous for age, gender and residential area, consisted of 41 children. In order to reduce the blood concentrations of the considered toxic metals, 4 enterosorbents were tested and prescribed for 2 consecutive weeks of therapy: Enterosgel ®, Polysorb™, Polyphepan, and activated charcoal. – Enterosgel ® - blood tests. Decrease from baseline: Mn = 12%; Ni = 64 %; Pb = 20 %; Cr = 56 %. – Polysorb™ - blood tests. Decrease from baseline: Mn = 24%; Ni = 65%; Pb = 20 %; Cr = 66%. – Polyphepan - blood tests. Decrease from baseline: Mn = 0 %; Ni = 51 %; Pb = 12%; Cr = 61 %. – Activated charcoal - blood tests. Decrease from baseline: Mn = 0 %; Ni = 69 %; Pb = 10 %; Cr = 44%. Data reveal that the use of Enterosgel ® and Polysorb™ for 2 consecutive weeks allows to obtain a significant reduction – compared to the controls – of the amount of Cr and Ni (56-66%) and Mn and Pb (12-24%) in the blood of asthmatic children living in poor sanitary conditions.

KEY WORDS: ENTEROSORBENTS, ENTEROSGEL®, MANGANESE, NICKEL, LEAD, CHROME, POLLUTION. 

Icon
ENTEROSORPTION METHOD IN THE TREATMENT OF INTOXICATION SYNDROME, 2011

Yulish E.I., Krivuschev B.I.

Summary
The work focuses on the role of the toxic syndrome and endointoxemia in the pathogenesis of infectious and noninfectious diseases. Enterosorption method in the treatment of endotoxemia is analyzed.

Keywords
Endotoxemia, enterosorption, sorbents. 

Icon
RELIEF OF ACUTE ALCOHOL INTOXICATION WITH ENTEROSGEL, 2014

Volkov M.Y., Tkachenko E.I., Avaluyeva E.B., Ivanov S.V., Lapinsky I.V., Matsievsky N.A.

Icon
SINGLE-CENTER, PROSPECTIVE, OPEN, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTEROSGEL DESIGNATED TO TREAT DIARRHEA-DOMINANT IRRITABLE BOWEL SYNDROME, 2014

Tkachenko E.I., Avalueva E.B., Skazyvaeva E.V., Ivanov S.V., Lapinskii I.V., Pushkina A.V.

CONCLUSIONS
- Enterosgel® has a positive effect on the clinical performance, reducing abdominal pain severity and normalizing stool frequency in D-IBS patients, thus contributing to the harmonization of quality of life.
- On the background of administration of Enterosgel® in D-IBS patients, a decrease of GIT dysbiosis signs is observed, improving the quantitative and qualitative microflora composition of thecolon.
- Enterosgel® is well-tolerated, safe and can be recommended for use in D-IBS patients.
- Treatment regimens that can be recommended for use in patients with D-IBS: 22.5 g of the paste with the active substance polymethylsiloxane polyhydrate 3 times a day 1 hour after meal orally for 3 consecutive weeks (paste dose should be dissolved in 200 ml of cool boiled water or washed down with at least 200 ml of cool boiled water). 

Icon
EFFICIENCY AND SAFETY OF SILICON-CONTAINING ENTEROSORBENT IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME, 2014

Tkachenko E.I., Avalueva E.B., Skazyvaeva E.V., Ivanov S.V., Pushkina A.V., Lapinskii I.V.

Summary

Enterosgel® has a positive effect on the clinical performance, reducing abdominal pain severity and normalizing stool frequency in D-IBS patients, thus contributing to the harmonization of quality of life.
Treatment regimens that can be recommended for use in patients with D-IBS: 22.5 g of the paste with the active substance polymethylsiloxane polyhydrate 3 times a day 1 hour after meal orally for 3 consecutive weeks (paste dose should be dissolved in 200 ml of cool boiled water or washed down with at least 200 ml of cool boiled water). 

Icon
STUDY OF THE CHARACTER OF INFLUENCE OF THE DRUG ENTEROSGEL ON SEVERITY OF INTOXICATION IN HEALTHY INDIVIDUALS, 2014

Tkachenko E.I., Avalueva E.B., Ivanov S.V., Lapinskii I.V.

Conclusion

Drug Enterosgel® at a dose of 45 g did not show statistically proven impact on the dynamics of the amount of ethanol vapor in the breath after drinking a strong alcoholic drink (whiskey Jameson 40%) in 100 ml while taking the drug after 60 min and 120 min after drinking alcohol but there was a trend to a more rapid decrease in the concentration of alcohol in the breath while taking the drug Enterosgel® by 3rd hour from the moment of reception of alcohol. Proven effect of the study drug was detected in case of the use of strong alcoholic drink (whiskey Jameson 40%) 200 ml. Subjective sensation of sobering speed did not change in patients receiving the study drug.
Thus, the drug Enterosgel® at a dose of 45 g has an impact on the dynamics of amount of ethanol vapor in expired air after administration of a strong alcoholic drink, which manifests itself as a more pronounced decrease in the amount of ethanol vapor in exhaled air over time. The effect has been identified while taking the drug both after 60 min and 120 min after drinking. 

Icon
EFFICIENCY AND SAFETY OF ENTEROSGEL (POLYMETHYLSILOXANE POLYHYDRATE) IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME, 2015

Tkachenko E.I., Avalueva E.B., Skazyvaeva E.V., Ivanov S.V., Pushkina A.V., Lapinskii I.V.

Summary

Enterosgel has a positive effect on the clinical performance, reducing abdominal pain severity and normalizing stool frequency in D-IBS patients, thus contributing to the harmonization of quality of life.

Treatment regimens that can be recommended for use in patients with D-IBS: 22.5 g of the paste with the active substance polymethylsiloxane polyhydrate three times a day one hour after meal orally for three consecutive weeks (the dose should be dissolved in 200 ml of drinking water or washed down with at least 200 ml of drinking water). 

Icon
SINGLE-CENTER, PROSPECTIVE, OPEN, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THE ENTEROSGEL DESIGNATED TO TREAT HELICOBACTER PYLORI-ASSOCIATED CHRONIC GASTRODUODENITIS, 2014

Tkachenko E.I., Avalueva E.B., Skazyvaeva E.V., Ivanov S.V., Lapinskii I.V.

SUMMARY

Enterosgel has a positive effect on the clinical performance of the disease and is effective in reducing the symptoms of intestinal dyspepsia and diarrhea in patients with Helicobacter pylori-associated gastroduodenitis.

After a 21-day course of Enterosgel, severity of inflammatory changes in the mucosa of the upper GIT and stomach contamination with Helicobacter pylori significantly reduced in patients with Helicobacter pylori-associated gastroduodenitis, indicating its anti-inflammatory and anti-helicobacter action.

When using Enterosgel in patients with Helicobacter pylori-associated gastroduodenitis, quality of life and psycho-emotional state has improved.

Enterosgel drug was well-tolerated and safe when administered. 

Icon
ENTEROSGEL MEDICAL PREPARATION - THE RESULTS OF CLINICAL EFFICIENCY IN PATIENTS WITH DIGESTIVE SYSTEM-RELATED PATHOLOGY, 1999

Sokolov E.I., Majev I.V.

CONCLUSION: A total of 20 patients with chronic diarrhea (chronic enterocolitis, post-resection syndrome) was under clinical observation. In addition to the standard therapy, patients received Enterosgel in a daily dose of 45 g (per 15 g 3 times a day) for 14 days. The control group consisted of 18 patients comparable by primary diagnosis, gender and age. Therapeutic efficiency was evaluated according to the clinical data, coprological studies, dynamics of colonic microflora, endoscopic and histological analyses, immune status-related study and the complex biochemical research. A high clinical efficiency of Enterosgel preparation has been determined and its positive effect on the intestinal mucosa condition, digestion and absorption processes, the composition of small and large intestine-related microflora. The immunomodulative effect has been identified as conditioned by the normalization of eubiosis and the decreased inflammation activity in the intestinal mucosa. There were not revealed any side events and cases of intolerance when using the Enterosgel enterosorbent. Enterosgel is being recommended for a widespread use in the treatment of chronic digestive diseases that are accompanied by diarrhea syndrome and eubiosis impairment of small and large intestine. A long-term application of Enterosgel is purposeful to get the persistent therapeutic effect. 

Icon
ENTEROSGEL IN PEDIATRICS, 1999

Soboleva M.K., Zorkina T.V., Plotnikova O.V., Simantovskaya T.P., Golisheva M.N.

The problem of elimination of toxic substances from the body is one of the most pressing in pediatrics. Hemosorption, hemodialysis and plasmapheresis has been successfully used in pediatric practice for a long time; however, the risk of their use may exceed expediency in some cases (for example, in case of moderate toxicity). Pediatricians have been always interested in non-invasive detoxification methods, in this context we have piloted Enterosgel, a new enterosorbent, in addition to infusion therapy, plasmapheresis, and in some cases as the unique detoxification therapy. 


Please rate this information
  • 5/5
  • 1 rating
1 ratingX
Very bad! Bad Hmmm Oke Good!
0% 0% 0% 0% 100%